The variants of CREBBP gene account for 50%∼60%, which is called RSTS1 type; EP300 gene mutations account for 8%∼10%, which is called RSTS type 2, but about 30% of patients have no pathogenic genes (Yang and Chen, 2023; Sun et al., 2021). Here, EP300 is linked to Rubinstein-Taybi syndrome.